Fibromyalgia News and Research

Latest Fibromyalgia News and Research

Deconstruction of biomedical research on pain will improve diagnosis, treatment of chronic pain sufferers

Is the science of diagnosing pain causing a number of pain sufferers to defend their honor? Research out of the University of Cincinnati is examining the diagnosis of pain that evades scientific testing, and the additional emotional suffering that can result for the patient.

17 Aug 2010

Adeona reports $979,782 net income for second-quarter 2010 vs. $879,550 net loss for same period in 2009

Adeona Pharmaceuticals, Inc. announced its second quarter 2010 financial results and recent achievements.

16 Aug 2010

Chronic pain affects higher proportion of women than men: Research

Women experience chronic pain longer, more intensely and more often than men, according to a psychologist who works with both men and women dealing with diseases and conditions that leave them suffering.

13 Aug 2010

Jazz Pharmaceuticals second-quarter net product sales increase 49% to $39.5 million

Jazz Pharmaceuticals, Inc. announced financial results for the second quarter ended June 30, 2010 and updated financial guidance for 2010. The company's updated financial guidance reflects higher expected sales of XYREM® (sodium oxybate) and the effects of recent financing activities.

11 Aug 2010

Intrinsic brain connectivity in fibromyalgia associated with chronic pain intensity

A recent study from researchers at Massachusetts General Hospital and University of Michigan provides the first direct evidence of linkage between elevated intrinsic (resting-state) brain connectivity and spontaneous pain intensity in patients with fibromyalgia (FM). This research shows an interaction of multiple brain networks, offering greater understanding of how pain arises. Details of the study appear online and in the August issue of Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology.

30 Jul 2010

Resting brain activity associated with spontaneous fibromyalgia pain

29 Jul 2010

POA releases consensus statement on CIRS-WDB

Policyholders of America released a consensus statement written by treating physicians and researchers in the field on the mechanism and treatment of illness found in people sickened by exposure to water-damaged buildings. This illness has been the subject of heated debate that has resulted in harsh allegations being lobbed at patients by experts hired by industry to cast doubt on the legitimacy of the illness.

28 Jul 2010

Forest Laboratories reports first-quarter diluted EPS of $0.39

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $0.39 in the first quarter of fiscal 2011. Excluding the charge related to the United States Department of Justice investigations described below, and a charge of $50.0 million, or $0.17 per share net of tax, for a new product licensing fee, non-GAAP earnings per share for the first fiscal quarter were $0.95 per share.

20 Jul 2010

Obesity, chronic pain linked to family history, mood disorders: Study

Though it is well known obese individuals have a high incidence of persistent pain problems, a new study in The Journal of Pain, published by the American Pain Society, reports that comorbid obesity and pain also are linked to family history and mood disorders.

20 Jul 2010

Adeona completes $1 million equity financing and provides update on Zinthionein ZC clinical study

Adeona Pharmaceuticals, Inc., announced today that on July 6, 2010, it completed an equity financing of $1 million with a single institutional investor, Seaside 88, L.P. The financing involved the sale of 1,212,121 registered shares of common stock and no warrants. Enclave Capital served as placement agent and will receive a 7% cash commission and 5-year warrants to acquire 60,606 shares of Adeona at $1.32 per share. The use of proceeds is intended for general corporate purposes.

6 Jul 2010

Chelsea reports positive outcome from DMC review of droxidopa Phase II trial in fibromyalgia

Chelsea Therapeutics International, Ltd. announced the completion and favorable outcome of an independent Data Monitoring Committee (DMC) review of the safety and efficacy data from approximately half the target enrollment in Chelsea's Phase II trial of droxidopa in fibromyalgia.

2 Jul 2010

Chelsea completes enrollment in Northera Phase III Study 301 for neurogenic orthostatic hypotension

Chelsea Therapeutics International, Ltd. has successfully reached its target enrollment of 150 patients in its Northera™ (Droxidopa) pivotal Phase III Study 301 for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH). Results from the trial are expected in September 2010 and the full registration program is on track to initiate a new drug application (NDA) in the first half of 2011.

30 Jun 2010

Chelsea initiates NORTHERA Phase III trial for symptomatic NOH associated with PD

Chelsea Therapeutics International, Ltd. announced the initiation of Study 306, a pivotal Phase III trial evaluating the efficacy of NORTHERA™, an oral synthetic precursor of norepinephrine, for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) associated with Parkinson's disease.

29 Jun 2010

JZP-6 to be reviewed at joint meeting for treatment of fibromyalgia

Jazz Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration's Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee will review JZP-6 (sodium oxybate) for the treatment of fibromyalgia at a joint meeting on August 20, 2010.

25 Jun 2010

Chelsea presents Northera study data at International Congress on Parkinson's Disease and Movement Disorders

Chelsea Therapeutics International, Ltd. announced that data from its pivotal studies of Northera™ (droxidopa) in symptomatic neurogenic orthostatic hypotension was presented during a poster session and featured in a symposium highlighting the role of norepinephrine (NE) deficiency in Parkinson's disease at the 14th International Congress on Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina.

17 Jun 2010

Adeona's HartLab expands diagnostic testing services to include full array of microbiology testing

Adeona Pharmaceuticals, Inc. announced that its wholly-owned CLIA-certified clinical testing subsidiary, HartLab, has expanded its in-house diagnostic testing services to include a full array of microbiology testing. Adeona believes that that this expansion of services will be accretive to HartLab's revenues in the current quarter and beyond and is consistent with Adeona's plans to continue to build the revenues of its HartLab subsidiary.

15 Jun 2010

Healthcore Media launches dynamic, educational and community-oriented health website

Healthcore Media, LLC has launched http://www.onehealth.com, a dynamic, educational and community-oriented health website that is quickly taking center stage among health portals. Chronic illnesses are at an all-time high, and unbiased medical information and supportive connections with others are taking top priority across the world. One Health has answered the call.

14 Jun 2010

Adeona completes 50% enrollment in Part 2 CopperProof-2 study of oral zinc cysteine for Alzheimer's Disease

Adeona Pharmaceuticals, Inc. announced the completion of 50% enrollment in Part 2 of its clinical study, A Prospective, Randomized, Double Blind Trial of a Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease (CopperProof-2).

7 Jun 2010

Study provides personalized strategies to boost AIAA compliance in breast cancer patients

Aromatase inhibitor-associated arthralgia (AIAA) is a major side effect in breast cancer survivors, producing joint pain so severe that as many as ten percent of women discontinue their therapy prematurely while undergoing treatment with these lifesaving drugs.

3 Jun 2010

Genes influence AIAA side effect in breast cancer survivors

2 Jun 2010

Fibromyalgia News and Research

Latest Fibromyalgia News and Research

Deconstruction of biomedical research on pain will improve diagnosis, treatment of chronic pain sufferers

Adeona reports $979,782 net income for second-quarter 2010 vs. $879,550 net loss for same period in 2009

Chronic pain affects higher proportion of women than men: Research

Jazz Pharmaceuticals second-quarter net product sales increase 49% to $39.5 million

Intrinsic brain connectivity in fibromyalgia associated with chronic pain intensity

Resting brain activity associated with spontaneous fibromyalgia pain

POA releases consensus statement on CIRS-WDB

Forest Laboratories reports first-quarter diluted EPS of $0.39

Obesity, chronic pain linked to family history, mood disorders: Study

Adeona completes $1 million equity financing and provides update on Zinthionein ZC clinical study

Chelsea reports positive outcome from DMC review of droxidopa Phase II trial in fibromyalgia

Chelsea completes enrollment in Northera Phase III Study 301 for neurogenic orthostatic hypotension

Chelsea initiates NORTHERA Phase III trial for symptomatic NOH associated with PD

JZP-6 to be reviewed at joint meeting for treatment of fibromyalgia

Chelsea presents Northera study data at International Congress on Parkinson's Disease and Movement Disorders

Adeona's HartLab expands diagnostic testing services to include full array of microbiology testing

Healthcore Media launches dynamic, educational and community-oriented health website

Adeona completes 50% enrollment in Part 2 CopperProof-2 study of oral zinc cysteine for Alzheimer's Disease

Study provides personalized strategies to boost AIAA compliance in breast cancer patients

Genes influence AIAA side effect in breast cancer survivors

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Fibromyalgia News and Research

Latest Fibromyalgia News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in